E Vilar-Gomez1,2, L Calzadilla-Bertot1,3, S L Friedman4, B Gra-Oramas5, L Gonzalez-Fabian5, O Villa-Jimenez1, S Lazo-Del Vallin6, M Diago7, L A Adams3, M Romero-Gomez2, N Chalasani8. 1. Department of Hepatology, National Institute of Gastroenterology, Havana, Cuba. 2. Unit for the Clinical Management of Digestive Diseases, Virgen Macarena-Virgen del Rocio University Hospitals, Institute of Biomedicine, Ciberehd, University of Seville, Seville, Spain. 3. School of Medicine and Pharmacology, The University of Western Australia, Nedlands, WA, Australia. 4. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Department of Pathology, National Institute of Gastroenterology, Havana, Cuba. 6. Department of Radiology, National Institute of Gastroenterology, Havana, Cuba. 7. Liver Unit, Department of Gastroenterology, Valencia University General Hospital, Valencia, Spain. 8. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
BACKGROUND: Several recent studies have shown a strong association between non-alcoholic steatohepatitis (NASH) and chronic kidney disease. AIM: To examine the relationship between changes in liver histology and renal function in patients with NASH. METHODS: The present analysis represents a post hoc analysis of a recently published trial that included 261 patients with NASH who were treated with lifestyle modifications during 52 weeks. Kidney function was evaluated through Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rates (eGFR, mL/min/1.73 m2 ) overtime. We explored correlations between the kidney function and improvement in histological outcomes at 52 weeks. RESULTS: Interestingly, a one-stage reduction in fibrosis (r = 0.20, P < 0.01) and resolution of NASH (r = 0.17, P < 0.01) were significantly correlated with an improvement in the kidney function. The eGFR values significantly increased in patients with fibrosis improvement (+7.6 ± 6.5 mL/min/1.73 m2 ), compared to those without fibrosis improvement (-1.98 ± 6.4 mL/min/1.73 m2 ) (P < 0.01) at end of treatment (EOT). Likewise, NASH resolution was associated with an increase in eGFR compared with patients without NASH resolution (2.32 ± 7.8 mL/min/1.73 m2 vs. -1.04 ± 5.9 mL/min/1.73 m2 , P = 0.04) at EOT. After controlling for the confounders, the association between fibrosis improvement, NASH resolution and eGFR change remained significant (P < 0.05 for both). CONCLUSIONS: Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in NASH. As new drugs for NASH emerge, studies should address whether improvement in histology in response to pharmacotherapies yield the same improvement in kidney function as weight loss.
BACKGROUND: Several recent studies have shown a strong association between non-alcoholic steatohepatitis (NASH) and chronic kidney disease. AIM: To examine the relationship between changes in liver histology and renal function in patients with NASH. METHODS: The present analysis represents a post hoc analysis of a recently published trial that included 261 patients with NASH who were treated with lifestyle modifications during 52 weeks. Kidney function was evaluated through Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rates (eGFR, mL/min/1.73 m2 ) overtime. We explored correlations between the kidney function and improvement in histological outcomes at 52 weeks. RESULTS: Interestingly, a one-stage reduction in fibrosis (r = 0.20, P < 0.01) and resolution of NASH (r = 0.17, P < 0.01) were significantly correlated with an improvement in the kidney function. The eGFR values significantly increased in patients with fibrosis improvement (+7.6 ± 6.5 mL/min/1.73 m2 ), compared to those without fibrosis improvement (-1.98 ± 6.4 mL/min/1.73 m2 ) (P < 0.01) at end of treatment (EOT). Likewise, NASH resolution was associated with an increase in eGFR compared with patients without NASH resolution (2.32 ± 7.8 mL/min/1.73 m2 vs. -1.04 ± 5.9 mL/min/1.73 m2 , P = 0.04) at EOT. After controlling for the confounders, the association between fibrosis improvement, NASH resolution and eGFR change remained significant (P < 0.05 for both). CONCLUSIONS: Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in NASH. As new drugs for NASH emerge, studies should address whether improvement in histology in response to pharmacotherapies yield the same improvement in kidney function as weight loss.
Authors: Manuela Abbate; Catalina M Mascaró; Sofía Montemayor; María Barbería-Latasa; Miguel Casares; Cristina Gómez; Escarlata Angullo-Martinez; Silvia Tejada; Itziar Abete; Maria Angeles Zulet; Antoni Sureda; J Alfredo Martínez; Josep A Tur Journal: Nutrients Date: 2021-02-15 Impact factor: 5.717
Authors: Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico Journal: Int J Environ Res Public Health Date: 2019-09-14 Impact factor: 3.390
Authors: Theresa Hydes; Ryan Buchanan; Oliver J Kennedy; Simon Fraser; Julie Parkes; Paul Roderick Journal: BMJ Open Date: 2020-09-28 Impact factor: 2.692